Reports Q3 revenue $8.37M, consensus $18.68M. "During our inaugural R&D Day and throughout subsequent scientific meetings this fall, we have shared promising nonclinical and clinical data that supports the best-in-class potential for our lead program ALPN-303 in multiple autoimmune and inflammatory indications. In particular, recent data from healthy volunteers presented at ASN’s Kidney Week demonstrated dose-dependent reductions in Gd-IgA1, a key effector molecule and clinical biomarker of disease progress in IgAN, and the first clinical disease-related biomarker data with ALPN-303," said Mitchell H. Gold, MD, Executive Chairman and Chief Executive Officer of Alpine. "To further accelerate development of this promising program in multiple indications, we completed a successful $113 million follow-on offering with top-tier investors in October, extending our cash runway through the end of 2025. We now look forward to beginning a broad development plan for ALPN-303, including a phase 2 study in systemic lupus erythematosus (SLE). In addition, we are particularly excited to begin open-label basket studies in glomerulonephritis and autoimmune cytopenias as they should provide a rapid assessment in multiple diseases and may potentially enable multiple accelerated development paths."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALPN:
- Alpine Immune price target lowered to $14 from $17 at Oppenheimer
- Alpine Immune Sciences price target lowered to $8 from $21 at H.C. Wainwright
- Alpine Immune Sciences Stock (NASDAQ:ALPN) Falls after Patient Death
- Alpine Immune Sciences terminates enrollment of davoceticept clinical studies
- Alpine Immune Sciences 13.6M share Spot Secondary priced at $7.35